tiprankstipranks
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
US Market
ACRS
Aclaris Therapeutics
RESEARCH TOOLSreports
Want to see ACRS full AI Analyst Report?

Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

896 Followers
See the Price Targets and Ratings of:

ACRS Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Aclaris
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACRS Stock 12 Month Forecast

Average Price Target

$10.80
▲(174.81% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $10.80 with a high forecast of $16.00 and a low forecast of $8.00. The average price target represents a 174.81% change from the last price of $3.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.14,5.052307692307692,5.964615384615384,6.8769230769230765,7.789230769230769,8.701538461538462,9.613846153846154,10.526153846153846,11.438461538461539,12.350769230769231,13.263076923076923,14.175384615384615,15.087692307692308,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.14,4.6523076923076925,5.164615384615384,5.676923076923076,6.189230769230769,6.701538461538462,7.213846153846154,7.726153846153846,8.23846153846154,8.75076923076923,9.263076923076923,9.775384615384617,10.287692307692307,{"y":10.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.14,4.436923076923077,4.733846153846153,5.030769230769231,5.327692307692308,5.624615384615384,5.921538461538462,6.218461538461538,6.515384615384615,6.812307692307693,7.109230769230769,7.406153846153846,7.703076923076923,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$10.80Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on ACRS
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$10
Buy
154.45%
Upside
Reiterated
04/16/26
Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Oppenheimer Analyst forecast on ACRS
Jeff Jones
Oppenheimer
Oppenheimer
$10
Buy
154.45%
Upside
Initiated
04/16/26
Aclaris Therapeutics initiated with an Outperform at OppenheimerAclaris Therapeutics initiated with an Outperform at Oppenheimer
Craig-Hallum Analyst forecast on ACRS
Adam Vogel
Craig-Hallum
Craig-Hallum
$10
Buy
154.45%
Upside
Reiterated
04/16/26
Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum
H.C. Wainwright Analyst forecast on ACRS
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$16
Buy
307.12%
Upside
Reiterated
04/15/26
Aclaris Therapeutics: Advancing ATI-052 and Bosakitug Pipeline Underpins Buy Rating and $16 Price Target
Wedbush Analyst forecast on ACRS
Martin Fan
Wedbush
Wedbush
$8
Buy
103.56%
Upside
Reiterated
01/20/26
Leerink Partners Analyst forecast on ACRS
Thomas Smith
Leerink Partners
Leerink Partners
$7
Buy
78.12%
Upside
Reiterated
10/15/25
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Aclaris Therapeutics (NASDAQ: ACRS)
Piper Sandler Analyst forecast on ACRS
Biren Amin
Piper Sandler
Piper Sandler
$6
Buy
52.67%
Upside
Reiterated
10/15/25
Piper Sandler Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Cantor Fitzgerald Analyst forecast on ACRS
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/15/25
Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)
Scotiabank Analyst forecast on ACRS
Louise Chen
Scotiabank
Scotiabank
$9
Buy
129.01%
Upside
Reiterated
07/30/25
Analysts Are Bullish on These Healthcare Stocks: Aclaris Therapeutics (ACRS), Nuvation Bio (NUVB)
Jefferies Analyst forecast on ACRS
Roger Song
Jefferies
Jefferies
$7
Buy
78.12%
Upside
Reiterated
04/24/25
Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on ACRS
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$10
Buy
154.45%
Upside
Reiterated
04/16/26
Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Oppenheimer Analyst forecast on ACRS
Jeff Jones
Oppenheimer
Oppenheimer
$10
Buy
154.45%
Upside
Initiated
04/16/26
Aclaris Therapeutics initiated with an Outperform at OppenheimerAclaris Therapeutics initiated with an Outperform at Oppenheimer
Craig-Hallum Analyst forecast on ACRS
Adam Vogel
Craig-Hallum
Craig-Hallum
$10
Buy
154.45%
Upside
Reiterated
04/16/26
Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum
H.C. Wainwright Analyst forecast on ACRS
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$16
Buy
307.12%
Upside
Reiterated
04/15/26
Aclaris Therapeutics: Advancing ATI-052 and Bosakitug Pipeline Underpins Buy Rating and $16 Price Target
Wedbush Analyst forecast on ACRS
Martin Fan
Wedbush
Wedbush
$8
Buy
103.56%
Upside
Reiterated
01/20/26
Leerink Partners Analyst forecast on ACRS
Thomas Smith
Leerink Partners
Leerink Partners
$7
Buy
78.12%
Upside
Reiterated
10/15/25
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Aclaris Therapeutics (NASDAQ: ACRS)
Piper Sandler Analyst forecast on ACRS
Biren Amin
Piper Sandler
Piper Sandler
$6
Buy
52.67%
Upside
Reiterated
10/15/25
Piper Sandler Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Cantor Fitzgerald Analyst forecast on ACRS
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/15/25
Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)
Scotiabank Analyst forecast on ACRS
Louise Chen
Scotiabank
Scotiabank
$9
Buy
129.01%
Upside
Reiterated
07/30/25
Analysts Are Bullish on These Healthcare Stocks: Aclaris Therapeutics (ACRS), Nuvation Bio (NUVB)
Jefferies Analyst forecast on ACRS
Roger Song
Jefferies
Jefferies
$7
Buy
78.12%
Upside
Reiterated
04/24/25
Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aclaris Therapeutics

3 Months
xxx
Success Rate
9/11 ratings generated profit
82%
Average Return
+38.69%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +38.69% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
10/11 ratings generated profit
91%
Average Return
+78.52%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +78.52% per trade.
2 Years
xxx
Success Rate
10/11 ratings generated profit
91%
Average Return
+81.75%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +81.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACRS Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
6
8
9
10
8
Buy
1
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
9
10
8
In the current month, ACRS has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACRS average Analyst price target in the past 3 months is 10.80.
Each month's total comprises the sum of three months' worth of ratings.

ACRS Financial Forecast

ACRS Earnings Forecast

Next quarter’s earnings estimate for ACRS is -$0.16 with a range of -$0.18 to -$0.12. The previous quarter’s EPS was -$0.16. ACRS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACRS has Performed in-line its overall industry.
Next quarter’s earnings estimate for ACRS is -$0.16 with a range of -$0.18 to -$0.12. The previous quarter’s EPS was -$0.16. ACRS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACRS has Performed in-line its overall industry.

ACRS Sales Forecast

Next quarter’s sales forecast for ACRS is $1.24M with a range of $0.00 to $2.40M. The previous quarter’s sales results were $1.29M. ACRS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACRS has Performed in-line its overall industry.
Next quarter’s sales forecast for ACRS is $1.24M with a range of $0.00 to $2.40M. The previous quarter’s sales results were $1.29M. ACRS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACRS has Performed in-line its overall industry.

ACRS Stock Forecast FAQ

What is ACRS’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is 10.80.
    What is ACRS’s upside potential, based on the analysts’ average price target?
    Aclaris Therapeutics has 174.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACRS a Buy, Sell or Hold?
          Aclaris Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Aclaris Therapeutics’s price target?
            The average price target for Aclaris Therapeutics is 10.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $8.00. The average price target represents 174.81% Increase from the current price of $3.93.
              What do analysts say about Aclaris Therapeutics?
              Aclaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of ACRS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.